Engene/EnGene reported additional preliminary pivotal‑cohort data for its nonviral gene therapy, detalimogene voraplasmid, in high‑risk BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ. The company said the new tranche of data supports a planned Biologics License Application next year and stock reaction reflected investor confidence in the program’s registrational trajectory.